Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) is advancing a novel approach to cancer treatment, according to Chief Medical Officer Dr. Islam Mohamed, who discussed the company's lead drug candidate ONC010 during an appearance on the IBN BioMedWire Podcast. The podcast, which focuses on developments in biotechnology and life sciences, provided a platform for Mohamed to outline the science behind ONC010 and its planned first-in-human clinical program.
ONC010 targets polynucleotide kinase phosphatase (PNKP), a DNA repair enzyme that plays a critical role in maintaining genomic integrity. By inhibiting PNKP, the drug aims to disrupt the ability of cancer cells to repair damaged DNA, leading to cell death. Mohamed emphasized two key selectivity mechanisms that are designed to enhance the drug's safety and efficacy. The first is synthetic lethality, which means the drug is intended to be lethal primarily to cancer cells that have lost the tumor suppressors PTEN or SHP-1. This approach could spare healthy cells and reduce side effects. The second mechanism is nanoparticle delivery, which is intended to concentrate the drug within tumor tissue, further limiting systemic exposure.
Preclinical research conducted at the University of Alberta has shown promising results. According to Mohamed, the nano-formulated PNKP inhibitor demonstrated single-agent antitumor activity, was tolerated at tested doses, and prolonged survival relative to controls. These findings provide a foundation for the company's planned first-in-human clinical program, which will be a critical step in translating the preclinical promise into a potential therapy for patients.
The importance of this development lies in the urgent need for new cancer treatments, particularly for patients whose tumors have become resistant to existing therapies. By targeting a novel DNA damage response pathway, ONC010 represents a potential new class of cancer drugs. If successful in clinical trials, it could offer a new option for patients with cancers characterized by PTEN or SHP-1 deficiencies, which are common in many cancer types. The dual selectivity mechanisms could also improve the therapeutic window, making the treatment more tolerable than conventional chemotherapies.
Onco-Innovations holds an exclusive worldwide licence to patented technology directed to the therapeutic inhibition of PNKP. The company is dedicated to cancer research and treatment, with a mission to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. For investors and industry observers, the progress of ONC010 will be closely watched as it enters the clinic. Updates relating to ONNVF are available in the company's newsroom at https://ibn.fm/ONNVF. The full press release can be viewed at https://ibn.fm/XgpMR.
The BioMedWire Podcast is part of a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. It is one of more than 75 brands within the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions, article and editorial syndication to over 5,000 outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. With broad reach and a seasoned team, BioMedWire aims to serve private and public companies seeking to reach investors, influencers, consumers, journalists, and the general public. More information is available at https://www.BioMedWire.com.
As Onco-Innovations moves toward clinical testing, the implications for the oncology field are significant. A successful PNKP inhibitor could validate a new target and pave the way for additional therapies in this space. For patients, it offers hope for more effective and less toxic treatments. For the biotechnology industry, it underscores the importance of continued investment in innovative research and development. The coming months will be crucial as the company prepares to initiate its first-in-human study, marking a key milestone in its mission to combat cancer.
